Tucatinib: A Breakthrough in Advanced Breast Cancer Therapy
Siddhi Parab, Aanchal Gvalani, Priyanka Das, Sunaina Anand & Anish Desai · International Research Journal of Oncology · 2024
Tucatinib is a highly selective tyrosine kinase inhibitor targeting the HER2 protein, representing a significant advancement in treating HER2-positive metastatic breast cancer (MBC), including cases with brain metastases. This review assesses the efficacy and safety of tucatinib...
Open access
Research Article